Methods for Treating Cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Sep 20, 2007
app pub date -
Feb 22, 2007
filing date -
Feb 27, 2006
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure here enables a new breast cancer treatment strategy that combines the inhibition HMG-CoA reductase or protein geranylgeranylation and the promotion of nitric oxide formation by iNOS.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully